↓ Skip to main content

Identification of a novel, fast-acting GABAergic antidepressant

Overview of attention for article published in Molecular Psychiatry, March 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
76 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Identification of a novel, fast-acting GABAergic antidepressant
Published in
Molecular Psychiatry, March 2017
DOI 10.1038/mp.2017.14
Pubmed ID
Authors

K M J McMurray, M J Ramaker, A M Barkley-Levenson, P S Sidhu, P K Elkin, M K Reddy, M L Guthrie, J M Cook, V H Rawal, L A Arnold, S C Dulawa, A A Palmer

Abstract

Current pharmacotherapies for depression exhibit slow onset, side effects and limited efficacy. Therefore, identification of novel fast-onset antidepressants is desirable. GLO1 is a ubiquitous cellular enzyme responsible for the detoxification of the glycolytic byproduct methylglyoxal (MG). We have previously shown that MG is a competitive partial agonist at GABA-A receptors. We examined the effects of genetic and pharmacological inhibition of GLO1 in two antidepressant assay models: the tail suspension test (TST) and the forced swim test (FST). We also examined the effects of GLO1 inhibition in three models of antidepressant onset: the chronic FST (cFST), chronic mild stress (CMS) paradigm and olfactory bulbectomy (OBX). Genetic knockdown of Glo1 or pharmacological inhibition using two structurally distinct GLO1 inhibitors (S-bromobenzylglutathione cyclopentyl diester (pBBG) or methyl-gerfelin (MeGFN)) reduced immobility in the TST and acute FST. Both GLO1 inhibitors also reduced immobility in the cFST after 5 days of treatment. In contrast, the serotonin reuptake inhibitor fluoxetine (FLX) reduced immobility after 14, but not 5 days of treatment. Furthermore, 5 days of treatment with either GLO1 inhibitor blocked the depression-like effects induced by CMS on the FST and coat state, and attenuated OBX-induced locomotor hyperactivity. Finally, 5 days of treatment with a GLO1 inhibitor (pBBG), but not FLX, induced molecular markers of the antidepressant response including brain-derived neurotrophic factor (BDNF) induction and increased phosphorylated cyclic-AMP response-binding protein (pCREB) to CREB ratio in the hippocampus and medial prefrontal cortex (mPFC). Our findings indicate that GLO1 inhibitors may provide a novel and fast-acting pharmacotherapy for depression.Molecular Psychiatry advance online publication, 21 March 2017; doi:10.1038/mp.2017.14.

X Demographics

X Demographics

The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Austria 1 1%
Unknown 75 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 20%
Researcher 11 14%
Student > Bachelor 11 14%
Student > Master 10 13%
Student > Postgraduate 5 7%
Other 9 12%
Unknown 15 20%
Readers by discipline Count As %
Neuroscience 16 21%
Biochemistry, Genetics and Molecular Biology 7 9%
Agricultural and Biological Sciences 7 9%
Medicine and Dentistry 7 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 11 14%
Unknown 24 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 121. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2020.
All research outputs
#320,552
of 24,167,226 outputs
Outputs from Molecular Psychiatry
#295
of 4,355 outputs
Outputs of similar age
#7,106
of 312,904 outputs
Outputs of similar age from Molecular Psychiatry
#12
of 92 outputs
Altmetric has tracked 24,167,226 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,355 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,904 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.